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Pragmatic randomised controlled trial of a personalised intervention for carers of
people requiring home oxygen therapy
Abstract
© The Author(s) 2020. We used a pragmatic randomised controlled trial to evaluate a behavioural change
strategy targeting carers of chronically hypoxaemic patients using long-term home oxygen therapy.
Intervention group carers participated in personalised educational sessions focusing on motivating
carers to take actions to assist patients. All patients received usual care. Effectiveness was measured
through a composite event of patient survival to hospitalisation, residential care admission or death to 12
months. Secondary outcomes at baseline, 3, 6 and 12 months included carer and patient emotional and
physical well-being. No difference between intervention (n = 100) and control (n = 97) patients was found
for the composite outcome (hazard ratio (HR) 1.22, 95% confidence interval (CI) = 0.89, 1.68; p = 0.22).
Improved fatigue, mastery, vitality and general health occurred in intervention group patients (all p values
< 0.05). No benefits were seen in carer outcomes. Mortality was significantly higher in intervention
patients (HR = 2.01, 95% CI = 1.00, 4.14; p = 0.05; adjusted for Australia-modified Karnofsky Performance
Status), with a significant diagnosis–intervention interaction (p = 0.028) showing higher mortality in
patients with COPD (HR 4.26; 95% CI = 1.60, 11.35) but not those with interstitial lung disease (HR 0.83;
95% CI = 0.28, 2.46). No difference was detected in the primary outcome, but patient mortality was higher
when carers had received the intervention, especially in the most disabled patients. Trials examining
behavioural change interventions in severe disease should stratify for functionality, and both risks and
benefits should be independently monitored. Trial registration: Australian New Zealand Clinical Trials
Registry (ACTRN12607000177459).
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Abstract
We used a pragmatic randomised controlled trial to evaluate a behavioural change strategy targeting carers of
chronically hypoxaemic patients using long-term home oxygen therapy. Intervention group carers participated
in personalised educational sessions focusing on motivating carers to take actions to assist patients. All patients
received usual care. Effectiveness was measured through a composite event of patient survival to
hospitalisation, residential care admission or death to 12 months. Secondary outcomes at baseline, 3, 6 and
12 months included carer and patient emotional and physical well-being. No difference between intervention (n
¼ 100) and control (n ¼ 97) patients was found for the composite outcome (hazard ratio (HR) 1.22, 95%
confidence interval (CI) ¼ 0.89, 1.68; p ¼ 0.22). Improved fatigue, mastery, vitality and general health occurred
in intervention group patients (all p values < 0.05). No benefits were seen in carer outcomes. Mortality was
significantly higher in intervention patients (HR ¼ 2.01, 95% CI ¼ 1.00, 4.14; p ¼ 0.05; adjusted for Australiamodified Karnofsky Performance Status), with a significant diagnosis–intervention interaction (p ¼ 0.028)
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showing higher mortality in patients with COPD (HR 4.26; 95% CI ¼ 1.60, 11.35) but not those with interstitial
lung disease (HR 0.83; 95% CI ¼ 0.28, 2.46). No difference was detected in the primary outcome, but patient
mortality was higher when carers had received the intervention, especially in the most disabled patients. Trials
examining behavioural change interventions in severe disease should stratify for functionality, and both risks
and benefits should be independently monitored.
Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12607000177459).
Keywords
Chronic disease, caregivers, education, behavioural research, oxygen
Date received: 29 May 2019; accepted: 1 October 2019

Introduction
Long-term home oxygen therapy (HOT) may be prescribed in respiratory disease to control chronic
hypoxaemia and improve patient survival and health
status.1–3 Chronic obstructive pulmonary disease
(COPD), interstitial lung disease (ILD) and asthma
account for approximately 8.0% of all deaths in Australia4 and contribute to substantial worldwide morbidity and mortality.5 In South Australia, patients with
chronic hypoxaemia have long been approved for free
HOT supply if they meet criteria outlined in the 2005
Position Statement of the Thoracic Society of Australia and New Zealand.6
Despite considerable care needs, many patients with
severe respiratory disease live in the community7–8
requiring frequent medical attention,9 suffering depression and anxiety10 and cognitive impairment.5,11
Impacts on primary caregivers include psychological
strain, loss of social life, boredom and enmeshment
between patient and carer.10
Carer burden is widely acknowledged in relation to
many chronic diseases and disabilities. A review of
social support in COPD found variable associations
between patient and carer outcomes, such as quality
of life, physical functioning and self-rated health.12
Further, living with others and having a carer were
associated with higher levels of physical activity and
greater participation in pulmonary rehabilitation programmes than those without these supports.13 Carer
support may contribute to patients’ adherence to treatment protocols, potentially impacting patient morbidity and mortality, although effects of education
programmes for carers are unclear from the limited
research in the setting of chronic hypoxaemia.
Our theoretically informed carer-centred intervention used a social marketing framework and the

principles of academic detailing.14 Academic detailing was developed for use with health practitioners
but has more recently been used with patients.15 It
focused on training carers to support their contribution to the care of their patient requiring long-term
HOT, using evidence-based messages and therapeutic actions.14 Our primary hypothesis was that this
personalised behavioural change strategy, by helping
these carers gain confidence in patient care, would
lead to reduced patient hospitalisations, delayed
patient admission to residential care and improved
patient survival.

Methods
This study was designed as a pragmatic multicentre
randomised controlled trial. Patients approved for
Government-subsidised long-term HOT were identified as being eligible for enrolment in a carer–
patient dyad. While the caregiver was the focus of
the training strategy, the primary outcome was
patient-oriented.14

Participants and setting
Carers of patients receiving long-term HOT for
chronic hypoxaemia, living in independent accommodation and having at least one primary carer were
eligible.14 Between 2007 and 2009, carer–patient
dyads were recruited from three South Australian hospitals which had similar diagnostic and assessment
procedures and patient information delivery. Dyads
were randomised to intervention or control group stratified by referring hospital and new versus existing
HOT prescription. Each intervention dyad was
assigned to one of two research nurses who maintained contact with the allocated dyad throughout the
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Table 1. Secondary outcome measures.

Plan

To ensure the person has an action plan
for exacerbations and knows how to get
one if necessary.

Understand To ensure each person has an overall
understanding of the (medical)
treatment and skills and techniques to
participate in their own care.
Review

Establish a process where the plan is
regularly reviewed.

Partners

Take a partnership approach where
communication is around the roles and
opportunities for both the patient and
the carer.

Carers

The carer’s health and well-being is
important.

Figure 1. Academic detailing key messages.

trial’s duration. Details are provided in our previous
publication14 and Online Supplemental Material.

Intervention
Local experience with academic detailing for patients
and carers in the palliative care setting and for general
practitioners treating refractory breathlessness16,17
informed our carer-centred intervention14 (Online
Supplemental Material). The intervention took place
in the carer’s home and comprised two educational
visits by research nurses trained respiratory health and
social marketing principles (Online Supplemental
Material). Participants were not previously known to
these nurses. The intervention visits were directed
towards carers, aiming to motivate them to take
actions consistent with five key messages developed
a priori as important for carer and/or patient care
using best available evidence at the time (Figure 1).
Up to five messages were delivered, depending upon
the nurses’ expert assessment of carer needs at the
time of each visit. Although the intervention was
designed for and delivered to carers, patients were
permitted to attend sessions. Patients in both study
arms continued to receive usual care, which included
information about disease management and HOT use.

Ethics and privacy considerations
This trial was approved by the Flinders Clinical
Research Ethics Committee, Repatriation General
Hospital Research and Ethics Committee, Royal Adelaide Hospital Research Ethics Committee, and

Secondary outcome

Tool used

Who
completed?

Perceived caregiver
burden
Level of expected and
received social
support, social
activities and
provide service to
others
Perceived level of
mastery
Self-esteem
Health-related quality
of life (HRQoL) and
disability
Fatigue

Overload scale18

Carer

Anticipated and
received social
support (ARSS)
scale19

Carer

Mastery Scale20

Carer

Self-esteem scale21
SF3622

Carer
Carer and
patient

Identity – consequence Carer
fatigue scale (ICFS)23
Patient
Dyspnoea, fatigue,
Chronic respiratory
emotional function
questionnaire
and mastery
(CRQ)24

Australian Government Department of Veterans’
Affairs Human Research Ethics Committee.

Outcome measures
The primary outcome was a composite of patients’
survival time to hospitalisation, residential care admission or death over the course of 12 months. Secondary
outcome measures were perceived carer burden,18
level of expected and received social support,19 perceived level of mastery,20 self-esteem,21 health-related
quality of life (HRQoL),22 fatigue23,24 and respiratoryrelated health status24 (Table 1), were collected at baseline, 3, 6 and 12 months after the first visit.

Descriptive data
Demographic data were collected at baseline (Table
2). Spirometry was not included in qualifying criteria,
as several respiratory diseases were included, some
with little relationship to baseline lung function, and
spirometry was considered potentially unreliable and
a cause of undue discomfort in patients with advanced
disease.

Statistical analyses
Survival to hospitalisation, residential care admission
or death was measured as a composite; (post hoc this
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Table 2. Baseline characteristics patients and carers.a
Patients

Intervention,
n ¼ 100

Control,
n ¼ 97

75.3 + 8.8
65.0
92.0
6.0
26.1 + 6.5

73.6 + 9.4
58.8
85.6
6.2
26.3 + 6.1

Age (mean + SD; years)
Male (%)
Ever smoked (%)
Current smoker (%)
BMI (mean + SD; kg/m2)
Respiratory diagnosis (%)
COPD
Asthma
ILD
Other
AKPSb (mean + SD)

78.0
79.4
1.0
1.0
18.0
14.4
3.0
5.2
61.8 + 11.1 67.9 + 12.2

Carers

Intervention
n ¼ 100

Control
n ¼ 97

Age (mean + SD; years)
66.7 + 11.5 66.7 + 13.3
Male (%)
28.0
35.1
Relationship with patient (%)
Permanent partner
73.0
78.3
Son/daughter
23.0
13.4
Friend
2.0
3.1
Other
2.0
5.1
44 (40–48) 44 (39–48)
Self-esteemc (median (IQR))
8 (6–9)
7 (6–9)
Caregiver burdend (median
(IQR))
25.1 (4.7)
25.6 (5.1)
Masterye (mean + SD)
Social supportf
Anticipated (median (IQR))
9 (8–11)
9 (8–12)
Received (median (IQR))
25 (21–30) 27 (23–32)
SD: standard deviation; IQR: interquartile range; BMI: body mass
index; COPD: chronic obstructive pulmonary disease; ILD: interstitial lung disease; AKPS: Australia-modified Karnofsky Performance Status.
a
AKPS – Lower scores indicate greater functional impairment
with score range 0–100.
b
Difference between study groups: p < 0.001.
c
Measured with the self-esteem Scale.
d
Measured with the overload Scale.
e
Measured with the mastery Scale.
f
Measured with the anticipated and received social support Scale.

composite outcome was decomposed and survival
analysis for each of the three components was undertaken) Power calculations based on the composite
outcome suggested a recruitment sample of 300
would provide 80% power to detect a 16% absolute
risk reduction, assuming a 10% dropout rate to 135
dyads per arm.
Primary outcome analysis was conducted using
Kaplan–Meier survival curves and multivariate Cox
regression. Multilevel models with measures at baseline, 3, 6 and 12 months were used to assess

differences between the study arms for HRQoL and
other secondary outcomes. No imputation was conducted for missing data for secondary outcomes and
relied instead upon mixed effects models in which
missing data were assumed missing at random. All
main analyses were performed on an intention to treat
basis with all randomised subjects included in the
analysis. Subjects experiencing any of the three
events were followed until the date of the event and
subjects not experiencing an event were censored at
12 months follow-up. Analysis was performed using
STATA version 13.0. Two-sided a values (p < 0.05)
determined statistically significant differences
between groups for each outcome.
Post hoc analyses explored associations between
baseline characteristics and mortality using a nested
case-control design in which each ‘death’ was
frequency-matched with two ‘survivors’ based on
patient age, gender, intervention group, respiratory
diagnosis and carer relationship with the patient and
performed with SPSS v 22.0. Baseline information on
variables considered likely to be associated with
patient mortality was retrospectively collected. Univariate and multivariate binary logistic regression
were used to determine independent predictors of
death. Examining for collinearity, variables with
probability value <0.15 in univariate analyses were
included in a multivariate analysis final model.

Results
One hundred ninety-seven patients with their primary
carer were included as ‘dyads’. Patients had COPD
(78%), asthma, ILD, pulmonary hypertension and
bronchiectasis (Table 2). Dyads were randomised to
intervention (n ¼ 100) and control (n ¼ 97) arms and
were mostly in permanent partnerships (intervention,
73%; control, 78%) (Table 2). Baseline characteristics
were comparable between groups, with the exception
of Australia-modified Karnofsky Performance Status
(AKPS) for which control patients had significantly
higher scores (p < 0.001) indicating better performance
status. More intervention dyads failed to complete 12month assessments (patients n ¼ 40/100; carers n ¼ 20/
100) when compared to the control group (patients n ¼
19/97; carers n ¼ 10/97) (Figure 2).
There was no significant difference between the
two study arms for the composite survival primary
outcome (all 197 patients included; hazard ratio
(HR) ¼ 1.22, 95% confidence interval (CI) ¼ 0.89,
1.68; p ¼ 0.22; Figure 3). Decomposition of the
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Carers
n=197

Patients
n=197

Randomisation

Randomisation

Intervention group:
n=100

Intervention group:
n=100

Control group:
n=97

Withdrawn n=5
Death of patient n=1
Personal Issues n=1
No reason n=1
Carer unwell n=1
Uncontactable n=1

Withdrawn n=5
Death n=1
Personal Issues n=1
No reason n=1
Carer unwell n=1
Uncontactable n=1

House visit 1:
n=95

House visit 1:
n=95

Withdrawn n=8
Deaths: n=4
Poor health n=3
Personal issues n=1

Withdrawn n=8
Death n=4
Poor health n=3
Personal issues n=1
House visit 2:
n=87
Withdrawn n=2
Death n=1
Poor health n=1

3 months FU:
n=85
Withdrawn n=10
Death n=8
No reason n=1
Went into palliative
care n=1
6 months FU:
n=75
Withdrawn n=15
Death n=15

12 months FU:
n=60

Control group:
n=97

Withdrawn n=9
Death n=4
Went into
palliative care
n=2
No reason n=3

3 months FU:
n=88
Withdrawn n=6
Death n=3
Went into RC*
n=1
No reason n=2
6 months FU:
n=82
Withdrawn n=4
Death n=4

12 months FU:
n=78

House visit 2:
n=87
Withdrawn n=2
Death n=0
Moved interstate
n=1
3 months FU:
n=85
Withdrawn n=2
Death of patient
n=1
No reason n=1

6 months FU:
n=83
Withdrawn=3
Death of patient:
n=1
No reason=2
12 months FU:
n=80

Withdrawn n=7
Death n=1
Went into
palliative care
n=2
No reason n=2
Unable to
complete
questions n=1
Death of patient
n=1
3 months FU:
n=90
Withdrawn n=2
Went into RC*
n=1
No reason n=1

6 months FU:
n=88
Withdrawn=1
Went into RC
n=1
12 months FU:
n=87

Figure 2. Flow diagram of patients and carers through the HOT study. *Abbreviations: FU: follow-up; RC: residential care
admission.

primary outcome revealed no differences between
arms for hospitalisation (intervention, n ¼ 76; control,
n ¼ 66; HR ¼ 1.23, 95% CI ¼ 0.89, 1.72; p ¼ 0.21;
Figure 4) or residential care admission (intervention,
n ¼ 6; control, n ¼ 7; HR ¼ 0.91, 95% CI ¼ 0.31,
2.71; p ¼ 0.86; Figure 5), but a between-group significant difference in the number of patient deaths

(intervention, n ¼ 29; control, n ¼ 11; HR ¼ 2.73;
95% CI ¼ 1.36, 5.46; p < 0.005; Figure 6). This difference remained borderline-significant after adjusting for baseline AKPS (HR ¼ 2.01; 95% CI ¼ 1.00,
4.14; p ¼ 0.05; Figure 6. Adjustment for diagnosis did
not significantly change the effect on death (HR ¼
2.58; 95% CI ¼ 1.28, 5.19), although a significant
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Figure 3. Survival to hospitalisation, residential care
admission or death for intervention and control patients.
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Figure 5. Survival to admission to residential care for
intervention and control patients.

randomised groups for any secondary outcomes
(Online Supplemental Table 3S).

Post hoc analyses

Figure 4. Survival to hospitalisation for intervention and
control patients.

interaction between diagnosis and intervention (p ¼
0.028) demonstrated a higher risk of death in the intervention group compared to control for COPD patients
(HR ¼ 4.26; 95% CI ¼ 1.60, 11.35; p ¼ 0.004)
although not for ILD patients (HR ¼ 0.83; 0.28,
2.46; p ¼ 0.73).
Secondary outcome measure results (Online
Supplemental Material) over 12 months showed the
intervention was associated with significant
improvements in patients’ generic HRQoL (SF36
Vitality (p ¼ 0.013) and General Health (p ¼
0.021); Online Supplemental Table 1S) and in two
Chronic Respiratory Questionnaire (CRQ) domains:
Mastery (p ¼ 0.003) and Fatigue (p ¼ 0.015; Online
Supplemental Table 2S). For carers, there were no
statistically significant differences between

Characteristics of the 40 patients who died and 80
frequency-matched surviving patients showed baseline dyspnoea (CRQ), AKPS and partial pressure of
oxygen were significantly worse in those who died
during the 12 months after the intervention compared
to survivors (Online Supplemental Table 4S). Death
certificate access was not permitted by Ethics Committees, but utilisation data showed that 34 of the 40
patients had died during or immediately after a hospital admission, and the main hospital discharge diagnoses were listed as COPD (n ¼ 10), ILD (n ¼ 4),
respiratory failure (n ¼ 4) and lower respiratory tract
infections (n ¼ 6), with 10 non-respiratory discharge
codes. Overload and social functioning were worse in
the carers of patients who died (Online supplemental
Table 4S). AKPS was the only significant contributor
to predict death (odds ratio 0.95; 95% CI 0.92–0.99;
Online supplemental Table 5S).

Discussion
This was a pragmatic trial conducted to evaluate a
novel training intervention designed for carers involving carer–patient dyads prescribed Governmentsubsidised long-term HOT for chronic hypoxaemia
associated with a range of severe respiratory diseases.
While the target of the intervention was the carer, the
primary outcome was patient-focused. Results did not
support our primary hypothesis related to improved
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1.00

Survival

0.90

0.80

0.70

HR=2.73 (95%CI=1.36-5.46), p<0.005

0.60

Control -------- Intervention
0.50
0

2

4

6

8

10

12

Survival Unadjusted for AKPS - Months

1.00

Survival

0.90

between carer support and patient treatment adherence have been shown,12 and lack of social support
has been found to be a barrier to patient self-management.25 We hypothesised that the intervention would
reduce healthcare utilisation by enhancing the carer’s
competence and confidence in everyday patient support, thereby optimising patient adherence to treatment paradigms existing at that time. However,
promoting the carer’s input may have inadvertently
contributed to a perceived role conflict regarding the
patients managing themselves.26 Positioning patients
in a less operational role could have negatively influenced their coping strategy and reduced their active
self-management, ultimately leading to an increase of
deaths.27 Whereas we anticipated that the intervention
would improve carers’ confidence in managing care,
there were no positive outcomes detected in carers’
mastery or quality of life accompanying the patients’
improvements in mastery, generic HRQoL and General Health.
Several questions arise from these findings.

0.80

0.70

HR=2.01 (95%CI=1.00-4.14), p=0.05
0.60

Control -------- Intervention
0.50
0

2

4

6

8

10

12

Survival Adjusted for AKPS - Months

Figure 6. Survival to death for intervention and control
patients before and after adjustment for AKPS. AKPS:
Australia-modified Karnofsky Performance Status.

patient healthcare utilisation, as no difference
between study arms was found for the primary outcome – the composite of patients’ survival to hospital
or residential care admission or to death over the
course of 12 months.14 In fact, a significantly higher
mortality rate was detected in patients whose carers
received the intervention, despite beneficial changes
in some secondary outcomes such as patients’ selfreported overall health status. Whereas risk of death
was increased for intervention patients with COPD, it
was not for those with ILD. Post hoc analyses showed
that AKPS was a significant contributor to predicting
death. These important and unexpected findings warrant careful evaluation and discussion.
The intervention was directed towards carers in
anticipation of improved patient support. Links

1. Was the intervention a driver for carers and/or
patients to feel empowered to control deteriorating disease status without seeking outside
help? At first glance, the number of deaths
arising during or post-hospitalisation (34/40)
suggests that their choice to escalate care was
correct. We have no supportive evidence of
better decision-making since self-efficacy – a
person’s belief in their ability to perform relevant strategies28 – was not measured directly
and we did not monitor patient selfmanagement activities or their action plan use.
2. Was the balance between ‘oxygen as panacea’,
‘oxygen as a burden’ and ‘antecedents to
beliefs’ 29 disturbed by the intervention?
Patients and carers often assume that oxygen
reduces dyspnoea or enables better functioning, but when they learnt that these were not
the purpose of the treatment, the perceived
positive association with oxygen provision
could have been unsettled With greater knowledge, patients and their carers might also see
HOT as a hindrance to their activities and
social interactions, and become aware of
potential dangers, so negative perceptions of
HOT could have been enhanced following the
intervention.
3. Did dyads actively consider end of life care as
part of what they perceived as better disease
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management? Another non-pharmacological
disease management modality with strong evidence for improved patient outcomes – pulmonary rehabilitation – is strongly associated
with effective social support, better selfmanagement, self-efficacy, and changes in
HRQoL, which can predict adaptive alterations in illness perceptions.30 Our intervention, which involved primarily the carer,
could have enhanced patient awareness of
their severe disease status and the burden
placed on their carer, or a realisation that
death was an imminent outcome, resulting
in the patient ‘letting go’. At the time this
study commenced, discussions with patients
about directing their advanced care were not
routine, and it was not actively addressed at
any time by the research nurses.
At least one other large study targeting behavioural
change in respiratory patients conducted around the
time of our trial found unexplained increased mortality,31 and the independent Data and Safety Monitoring Board (DSMB) stopped that trial before
completion. It should not be assumed that behavioural
modification interventions are entirely safe, and we
agree that DSMBs should be routinely instituted in
such trials,31 while considering the value of best supportive care alongside the value of trial information.31
Post hoc analyses revealed that three factors did
show statistically significant univariate associations
with poor survival: patients’ resting arterial blood
oxygenation, their level of perceived dyspnoea and
their performance status. Taken together, these are
consistent with more severe functional impairment,
but AKPS was the sole contributor to the multifactorial prediction model. AKPS is used in palliative care
settings to assess performance status and provides a
guide to prognosis,33 although patients enrolled in this
study were not receiving formal palliative care. The
mortality differential between study arms was smaller
after adjustment for AKPS but did remain significant.
This study had several strengths. The sample size
and 12-month follow-up allowed time to detect meaningful differences in the primary composite outcome,
which was chosen for relevancy to both clinical outcomes and potentially healthcare utilisation. We had
reasoned that the latter could inform health policy if
savings through reduced healthcare utilisation were
demonstrated. Importantly, composite scores were
deconstructed for interpretation and generalisability34

and this uncovered the significant imbalance in mortality. Finally, index patients with a variety of lung
diseases were recruited, with the explicit aim of
enhancing generalisability to typical HOT patients.
Messages were delivered based on carers’ needs, so
not all possible messages were delivered to all carers.
The message ‘to ensure the patient has an action plan
for COPD exacerbations or knows how to get one if
necessary’ was inherently restricted to carers of
COPD patients (78% of the intervention group). Seeking support earlier by contacting a healthcare provider
(in person or by telephone) or seeking emergency care
are important behaviours that could be influenced by
the presence of a carer. Intermediate outcomes,
including action plan use and dyad’s relationship
dynamics, would have been helpful in unravelling
the unexpected ‘death’ results. Unfortunately, this
information was not collected, and thus it remains
unclear whether this factor may have contributed to
differences between study arms. Additionally, we
had no lung function data at baseline, given the various diagnostic groups and patient severity. The variable we used to assess functional severity imposed
by the primary disease was the AKPS,33 developed
as a measure of functional status of patients with
terminal illnesses. We chose this as a descriptive
characteristic for patients but did not use it for
patient stratification. We assumed that any difference between intervention and control groups was
due to random variance among the multiple descriptive and outcome measures collected. If we had only
enrolled patients with COPD prescribed long-term
HOT, we could have explored associations between
spirometry and performance status or included other
performance criteria, such as 6-min walk distance.
However, our study population was non-diagnosisspecific, so these measurements were not available
for association analysis.
Because the patient participants generally had
severe respiratory disease, deaths were not unexpected, although the extent of imbalance in mortality
between groups was. In a 10-year survival analysis of
a HOT database in South Australia, the 12-month life
expectancy for COPD patients was 78.1% for COPD
patients. A systematic review of HOT in ILD showed
similar 12-month survival rates.35 In the present
study, control group patients had a better 12-month
survival (89%), whereas the 1-year survival in our
intervention group patients was slightly worse (71%).
This research was planned 15 years ago and was
completed 10 years ago. Despite the delay in
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providing the findings, the results remain relevant
today, since the criteria for treating hypoxaemic
patients with long-term HOT are unchanged and
patients needing this treatment are even more plentiful.
In fact, further research with such patient groups is now
warranted with an aim to provide insights into the
effects of actively involving primary carers in the support of patients. For future research we recommend:











Assessing complexities of patient–carer relationship dynamics with both qualitatively and
quantitatively;
Considering patient self-management strategies and behaviour, carer perceptions, and use
of advance care plans to understand the development of end-of-life decision-making in a
partnership;
Including larger numbers of patients with nonCOPD diagnoses to allow differentiating treatment effects between HOT-patient diagnosis
groups;
Stratifying patients by functional status, lung
function, activity and/or exercise capacity;
Structuring behaviour change interventions for
carers in active partnership with the patient to
enable engagement of both, especially in latestage disease;
Appointing a DSMB.

Conclusion
The primary outcome of this pragmatic trial in which
carers of patients using HOT received carer-centred
training was negative – there was no reduction in the
composite of patients’ survival to hospital or residential care admission or death over 12 months. However, there were significantly more deaths in the
intervention arm. Post hoc analyses showed the
increased risk of death was confined to intervention
patients with COPD, and between-group difference in
baseline performance status was a major contributor
to mortality imbalance. Future research evaluating
behaviour change interventions for carers of patients
with chronic hypoxaemia should take into account
complexities of patient–carer relationship dynamics
and stratify for patients’ functional status and diagnosis. We must also accept that behavioural change
interventions are not necessarily benign, and in recognising the possibility of consequences beyond
hypothesised benefits, an independent DSMB should
monitor both benefits and adverse events.

9

Acknowledgements
The authors thank Rosemary McCormick and Kerry Pascoe, research nurses from Southern Adelaide Local Health
Network, South Australia, Australia, who committed
wholly to the process of their own training, engaged participants and provided invaluable feedback to the investigators throughout the trial and during the discussions around
post hoc analysis. The authors acknowledge the contribution while on student secondment from the Netherlands of
Joanne Sloots who assisted with post hoc sub-analyses’
data collection. Without funding support from the Australian NHMRC (Project Grant 426737) for the study and its
approval to extend the time for supervision to undertake the
post hoc analyses, this report would have been impossible.

Data sharing statement
De-identified participant data will not be shared as included
participants have not consented to this. All available relevant information can be found in the clinical trial registry
and/or the online repository. No further information will be
publicly available.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest
with respect to the research, authorship, and/or publication
of this article.

Funding
The author(s) disclosed receipt of the following financial
support for the research, authorship, and/or publication of
this article: This work was financially supported by the
Australian NHMRC (Project Grant 426737).

ORCID iD
Tanja W Effing

https://orcid.org/0000-0003-3265-0131

Supplemental material
Supplemental material for this article is available online.

References
1. Crockett AJ, Cranston JM, Moss JR, et al. A review of
long-term oxygen therapy for chronic obstructive pulmonary disease. Respir Med 2001; 95: 437–443.
2. Hardinge M, Annandale J, Bourne S, et al. British
thoracic society guidelines for home oxygen use in
adults. Thorax 2015; 70(Suppl 1): i1–i43.
3. McDonald CF, Whyte K, Jenkins S, et al. Clinical
practice guideline on adult domiciliary oxygen therapy: executive summary from the Thoracic Society
of Australia and New Zealand. Respirology 2016; 21:
76–78.

10
4. Australian Institute of Health and Welfare. Asthma,
chronic obstructive pulmonary disease and other
respiratory diseases in Australia (ACM20). Canberra:
Australian Institute of Health and Welfare, 2010.
5. Collaborators GBDCRD. Global, regional, and
national deaths, prevalence, disability-adjusted
life years, and years lived with disability for
chronic obstructive pulmonary disease and asthma,
1990-2015: a systematic analysis for the Global
Burden of Disease Study 2015. Lancet Respir Med
2017; 5: 691–706.
6. McDonald CF, Crockett AJ and Young IH. Adult domiciliary oxygen therapy. Position statement of the
Thoracic Society of Australia and New Zealand. MJA
2005; 182: 621–626.
7. Kingston A, Wohland P, Wittenberg R, et al. Is
late-life dependency increasing or not? A comparison
of the Cognitive Function and Ageing Studies (CFAS).
Lancet 2017; 390: 1676–1684.
8. Harrop E, Byrne A and Nelson A. ‘It’s alright to ask for
help’: findings from a qualitative study exploring the
information and support needs of family carers at the
end of life. BMC Palliat Care 2014; 13: 22–32.
9. Lacasse Y, Rousseau L and Maltais F. Prevalence of
depressive symptoms and depression in patients with
severe oxygen-dependent chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2001; 21: 80–86.
10. Seamark DA, Blake SD, Seamark CJ, et al. Living with
severe chronic obstructive pulmonary disease (COPD):
perceptions of patients and their carers. An interpretative phenomenological analysis. Palliat Med 2004; 18:
619–625.
11. Pauwels RA, Buist AS, Calverley PM, et al. Global
strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.
NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J
Respir Crit Care Med 2001; 163: 1256–1276.
12. Chen Z, Fan VS, Belza B, et al. Association between
social support and self-care behaviors in adults with
chronic obstructive pulmonary disease. Ann Am
Thorac Soc 2017; 14: 1419–1427.
13. Barton C, Effing TW and Cafarella P.Social support
and social networks in COPD: A scoping review.
Chronic Obstruct Pulm Dis 2015; 12: 690–702.
14. Sladek RM, Jones T, Phillips PA, et al. Health, economic, psychological and social impact of educating
carers of patients with advanced pulmonary disease
(protocol). Contemp Clin Trials 2011; 32: 717–723.
15. Avorn J and Soumerai SB.Improving drug-therapy
decisions through educational outreach. A randomized

Chronic Respiratory Disease

16.

17.

18.

19.

20.
21.

22.

23.

24.

25.

26.

27.

28.

controlled trial of academically based ‘detailing’. N
Engl J Med 1983; 308: 1457–1463.
Abernethy A, Currow D, Shelby-James T, et al. Delivery strategies to optimize resource utilization and
performance status for patients with advanced
life-limiting illness: results from the ‘Palliative Care
Trial’ [ISRCTN 81117481]. J Pain Symptom Manag
2013; 45: 488–505.
Collier A, Rowett D, Allcroft P, et al. Academic detailing of general practitioners by a respiratory physician
for diagnosis and management of refractory breathlessness: a randomised pilot study. BMC Health Serv Res
2015; 15: 193–198.
Pearlin LI, Mullan JT, Semple SJ, et al. Caregiving and
the stress process: an overview of concepts and their
measures. Gerontologist 1990; 30: 583–594.
Schofield H, Murphy B, Herrman H, et al. Family
caregiving: measurement of emotional well-being and
various aspects of the caregiving role. Psychol Med
1997; 27: 647–657.
Pearlin LI, Schooler C and The structure of coping.
J Health Soc Behav 1978; 19: 2–21.
Bachman JG, O’Malley PM and Johnston J. Adolescence to adulthood. Ann Arbor: Institute for Social
Research, 1978.
South Australian Health Commission and Behavioural
Epidemiology Unit. South Australian population norms
for the short form (SF36) health status questionnaire.
Adelaide: South Australian Health Commission, 1995.
Paddison JS, Booth RJ, Hill AG, et al. Comprehensive
assessment of peri-operative fatigue: development of
the identity-consequences fatigue scale. J Psychosom
Res 2006; 60: 615–622.
Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung
disease. Thorax 1987; 42: 773–778.
Jerant AF, von Friederichs-Fitzwater MM and Moore
M. Patients’ perceived barriers to active
self-management of chronic conditions. Patient Educ
Couns 2005; 57: 300–307.
Tocchi C, McCorkle R and Knobf MT. Multidisciplinary specialty teams: a self-management program for
patients with advanced cancer. J Adv Pract Oncol
2015; 6: 408–416.
McPherson CJ, Hadjistavropoulos T, Devereaux A, et
al. A qualitative investigation of the roles and perspectives of older patients with advanced cancer and their
family caregivers in managing pain in the home. BMC
Palliat Care 2014; 13: 39.
Bandura A. Self-efficacy: the exercise of control. New
York: Freeman and Company, 1997.

Frith et al.
29. Kelly CA, Lynes D, O’Brien MR, et al. A wolf in
sheep’s clothing? Patients’ and healthcare professionals’ perceptions of oxygen therapy: an interpretative
phenomenological analysis. Clin Respir J 2018; 12:
616–632.
30. Bonsaksen T, Haukeland-Parker S, Lerdal A, et al. A
1-year follow-up study exploring the associations
between perception of illness and health-related quality of life in persons with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014; 9:
41–50.
31. Fan VS, Gaziano JM, Lew R, et al. A comprehensive
care management program to prevent chronic
obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med 2012; 156:
673–683.

11
32. Eckermann S, Karnon J and Willan AR. The value of
value of information: best informing research design
and prioritization using current methods. Pharmacoeconomics 2010; 28: 699–709.
33. Abernethy A, Shelby-James T, Fazekas B, et al. The
Australia-modified Karnofsky Performance Status
(AKPS) scale: a revised scale for contemporary palliative care clinical practice. BMC Palliat Care 2005; 4: 7.
34. DeWalt DA, Schillinger D, Ruo B, et al. Multisite
randomized trial of a single-session versus multisession literacy-sensitive self-care intervention for
patients with heart failure. Circulation 2012; 125:
2854–2862.
35. Crockett AJ, Cranston JM and Antic N. Domiciliary
oxygen for interstitial lung disease. Cochrane Database Syst Rev 2001; 3: CD002883.

